TOP: Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis
Status:
Completed
Trial end date:
2003-11-07
Target enrollment:
Participant gender:
Summary
This is an 18-month, double-blind, placebo-controlled, Phase III trial with a 12-month
interim analysis of the effect of ALX1-11, recombinant human parathyroid hormone (1-84)
(rhPTH [1-84]), on fracture incidence in women with postmenopausal osteoporosis, the TOP
study.